{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:23:21Z","timestamp":1794907401040,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Jiangsu Province","award":["BK20211221"],"award-info":[{"award-number":["BK20211221"]}]},{"name":"the Natural Science Foundation of Jiangsu Province","award":["BK20211221"],"award-info":[{"award-number":["BK20211221"]}]},{"DOI":"10.13039\/501100013910","name":"Wenzhou Institute, University of Chinese Academy of Sciences","doi-asserted-by":"crossref","award":["WIUCASQD2020014"],"award-info":[{"award-number":["WIUCASQD2020014"]}],"id":[{"id":"10.13039\/501100013910","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013910","name":"Wenzhou Institute, University of Chinese Academy of Sciences","doi-asserted-by":"crossref","award":["WIUCASQD2020014"],"award-info":[{"award-number":["WIUCASQD2020014"]}],"id":[{"id":"10.13039\/501100013910","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGJ22C100001"],"award-info":[{"award-number":["LGJ22C100001"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wenzhou Scientific Research Project","award":["Y2020175"],"award-info":[{"award-number":["Y2020175"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is a major type of inflammatory bowel disease (IBD), which could induce bloody stool, diarrhea, colon atrophy and eventually lead to colorectal cancer. The conventional daily oral administration of drugs only relieve the inflammatory response of colon in the short term, Biological agents such as antibody drugs has proven its efficiency in inhibiting colitis, while the low drug bioavailability means that large doses of antibodies are required, ultimately causing systemic toxicity. Small interfering RNA (siRNA) has significant advantages over antibody drugs in terms of safety and efficacy, and it have been widely applied as potential candidates for a variety of inflammation-related diseases. However, oral delivery of siRNA fails to overcome the degradation of the gastrointestinal environment to produce a significant therapeutic effect in ulcerative colitis. Herein, we design the hybrid delivery system that the siRNA loaded MOF encapsulated in the sodium alginate particles to overcome the barriers in the oral process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The hybrid delivery system (SA@MOF-siRNA\n                      <jats:sup>TNF\u03b1<\/jats:sup>\n                      ) was successfully constructed, and it could not only survive the low pH environment in the stomach and small intestine, but also taken up more by inflammatory macrophages, as well as released much more MOF-siRNA\n                      <jats:sup>TNF\u03b1<\/jats:sup>\n                      . Moreover, SA@MOF-siRNA\n                      <jats:sup>TNF\u03b1<\/jats:sup>\n                      tended to enriched and infiltrated into local colon tissues. As a result, SA@MOF-siRNA\n                      <jats:sup>TNF\u03b1<\/jats:sup>\n                      significantly reduced the progression of colitis, of which the treated mice did not experience significant weight loss, bloody stools and diarrhea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We confirmed that the formulation of hydrogel\u2013metal-organic framework hybrids could improve the protection of incorporated payload in the gastric and early small intestine, enhancing the delivery of MOF-siRNA to colon.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-022-01603-6","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T14:02:34Z","timestamp":1662386554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Hydrogel\u2013metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Meng","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212572","volume":"8","author":"K Tripathi","year":"2019","unstructured":"Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8: 212572.","journal-title":"Drugs Context"},{"issue":"1","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","volume":"17","author":"S Danese","year":"2020","unstructured":"Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol. 2020;17(1):1\u20132.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","volume":"49","author":"L Du","year":"2020","unstructured":"Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin N. 2020;49(4):643\u201354.","journal-title":"Gastroenterol Clin N"},{"key":"1603_CR4","first-page":"1","volume":"9","author":"M Kayal","year":"2020","unstructured":"Kayal M, Shah S. Ulcerative colitis: current and emerging treatment strategies. J Clin Med. 2020;9:1.","journal-title":"J Clin Med"},{"issue":"3","key":"1603_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537\u201349.","journal-title":"Gastroenterology"},{"issue":"5","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","volume":"6","author":"M De Vos","year":"2012","unstructured":"De Vos M, Dewit O, D\u2019Haens G, Baert F, Fontaine F, Vermeire S, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis. 2012;6(5):557\u201362.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"1603_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.crohns.2014.01.010","volume":"8","author":"K Thorlund","year":"2014","unstructured":"Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8(7):571\u201381.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1603_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10620-016-4398-5","volume":"62","author":"C Taxonera","year":"2017","unstructured":"Taxonera C, Iglesias E, Munoz F, Calvo M, Barreiro-de Acosta M, Busquets D, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci. 2017;62(2):481\u201390.","journal-title":"Dig Dis Sci"},{"key":"1603_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113058","volume":"494","author":"D Bosman-Schluep","year":"2021","unstructured":"Bosman-Schluep D, de Pril R, Verbaken B, Legent A, Stallen J, de Jong EC, et al. siRNA-based identification of IBD-related targets in human monocyte-derived dendritic cells. J Immunol Methods. 2021;494: 113058.","journal-title":"J Immunol Methods"},{"issue":"3","key":"1603_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146\u201357.","journal-title":"Nucleic Acid Ther"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.actbio.2019.12.005","volume":"103","author":"C He","year":"2020","unstructured":"He C, Yue H, Xu L, Liu Y, Song Y, Tang C, et al. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery. Acta Biomater. 2020;103:213\u201322.","journal-title":"Acta Biomater"},{"issue":"1","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/fcp.12561","volume":"35","author":"J Jiang","year":"2021","unstructured":"Jiang J, Zhang X, Tang Y, Li S, Chen J. Progress on ocular siRNA gene-silencing therapy and drug delivery systems. Fundam Clin Pharmacol. 2021;35(1):4\u201324.","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.7150\/thno.15710","volume":"6","author":"B Xiao","year":"2016","unstructured":"Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Hang MK, et al. Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation. Theranostics. 2016;6(12):2250\u201366.","journal-title":"Theranostics"},{"issue":"14","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1016\/j.biomaterials.2013.01.079","volume":"34","author":"J Zhang","year":"2013","unstructured":"Zhang J, Tang C, Yin C. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials. 2013;34(14):3667\u201377.","journal-title":"Biomaterials"},{"issue":"10","key":"1603_CR15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/ibd\/izz149","volume":"25","author":"D Yao","year":"2019","unstructured":"Yao D, Dong M, Dai C, Wu S. Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer. Inflamm Bowel Dis. 2019;25(10):1595\u2013602.","journal-title":"Inflamm Bowel Dis"},{"issue":"16","key":"1603_CR16","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2217\/nnm-2017-0196","volume":"12","author":"M Zhang","year":"2017","unstructured":"Zhang M, Wang X, Han MK, Collins JF, Merlin D. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine. 2017;12(16):1927\u201343.","journal-title":"Nanomedicine"},{"issue":"1","key":"1603_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2013.03.004","volume":"168","author":"J McCarthy","year":"2013","unstructured":"McCarthy J, O\u2019Neill MJ, Bourre L, Walsh D, Quinlan A, Hurley G, et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J Control Release. 2013;168(1):28\u201334.","journal-title":"J Control Release"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2018.08.021","volume":"287","author":"B Xiao","year":"2018","unstructured":"Xiao B, Chen Q, Zhang Z, Wang L, Kang Y, Denning T, et al. TNF alpha gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. J Control Release. 2018;287:235\u201346.","journal-title":"J Control Release"},{"issue":"7","key":"1603_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/10611860903057674","volume":"17","author":"S Akhtar","year":"2009","unstructured":"Akhtar S. Oral delivery of siRNA and antisense oligonucleotides. J Drug Target. 2009;17(7):491\u20135.","journal-title":"J Drug Target"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41598-018-20632-6","volume":"8","author":"RL Ball","year":"2018","unstructured":"Ball RL, Bajaj P, Whitehead KA. Oral delivery of siRNA lipid nanoparticles: fate in the GI tract. Sci Rep. 2018;8:2178.","journal-title":"Sci Rep"},{"issue":"6","key":"1603_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.addr.2012.11.003","volume":"65","author":"C Kriegel","year":"2013","unstructured":"Kriegel C, Attarwala H, Amiji M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv Drug Deliv Rev. 2013;65(6):891\u2013901.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"1603_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nmat2859","volume":"9","author":"DS Wilson","year":"2010","unstructured":"Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9(11):923\u20138.","journal-title":"Nat Mater"},{"issue":"23","key":"1603_CR23","doi-asserted-by":"publisher","first-page":"1606134","DOI":"10.1002\/adma.201606134","volume":"29","author":"M-X Wu","year":"2017","unstructured":"Wu M-X, Yang Y-W. Metal-organic framework (MOF)-based drug\/cargo delivery and cancer therapy. Adv Mater. 2017;29(23):1606134.","journal-title":"Adv Mater"},{"issue":"2","key":"1603_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1021\/acs.chemrev.9b00223","volume":"120","author":"Q Wang","year":"2020","unstructured":"Wang Q, Astruc D. State of the art and prospects in metal-organic framework (MOF)-Based and MOF-derived nanocatalysis. Chem Rev. 2020;120(2):1438\u2013511.","journal-title":"Chem Rev"},{"issue":"13","key":"1603_CR25","doi-asserted-by":"publisher","first-page":"eaa6108","DOI":"10.1126\/sciadv.aaz6108","volume":"6","author":"J Zhuang","year":"2020","unstructured":"Zhuang J, Gong H, Zhou J, Zhang Q, Gao W, Fang RH, et al. (2020) Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles. Sci Adv. 2020;6(13):eaa6108.","journal-title":"Sci Adv."},{"issue":"8","key":"1603_CR26","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1021\/acsami.6b12792","volume":"9","author":"Q Chen","year":"2017","unstructured":"Chen Q, Xu M, Zheng W, Xu T, Deng H, Liu J. Se\/Ru-decorated porous metal-organic framework nanoparticles for the delivery of pooled siRNAs to reversing multidrug resistance in taxol-resistant breast cancer cells. ACS Appl Mater Interfaces. 2017;9(8):6712\u201324.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1603_CR27","first-page":"103","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y, Zheng L, Yang Y, Qian X, Fu T, Li X, et al. Metal-organic framework nanocarriers for drug delivery in biomedical applications. Nanomicro Lett. 2020;12(1):103.","journal-title":"Nanomicro Lett"},{"issue":"20","key":"1603_CR28","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1016\/S0142-9612(03)00167-4","volume":"24","author":"L Wang","year":"2003","unstructured":"Wang L, Shelton RM, Cooper PR, Lawson M, Triffitt JT, Barralet JE. Evaluation of sodium alginate for bone marrow cell tissue engineering. Biomaterials. 2003;24(20):3475\u201381.","journal-title":"Biomaterials"},{"issue":"4","key":"1603_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1021\/acsbiomaterials.2c00047","volume":"8","author":"J Watchorn","year":"2022","unstructured":"Watchorn J, Clasky AJ, Prakash G, Johnston IAE, Chen PZ, Gu FX. Untangling mucosal drug delivery: engineering, designing, and testing nanoparticles to overcome the mucus barrier. ACS Biomater Sci Eng. 2022;8(4):1396\u2013426.","journal-title":"ACS Biomater Sci Eng"},{"issue":"7","key":"1603_CR30","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1039\/c0cc05002d","volume":"47","author":"Y Pan","year":"2011","unstructured":"Pan Y, Liu Y, Zeng G, Zhao L, Lai Z. Rapid synthesis of zeolitic imidazolate framework-8 (ZIF-8) nanocrystals in an aqueous system. Chem Commun. 2011;47(7):2071\u20133.","journal-title":"Chem Commun"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.actbio.2020.09.017","volume":"116","author":"M Naeem","year":"2020","unstructured":"Naeem M, Lee J, Oshi MA, Cao J, Hlaing SP, Im E, et al. Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomater. 2020;116:368\u201382.","journal-title":"Acta Biomater"},{"issue":"6","key":"1603_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1586\/egh.11.74","volume":"5","author":"IC Roberts-Thomson","year":"2011","unstructured":"Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol. 2011;5(6):703\u201316.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1603_CR33","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238.","journal-title":"J Immunol Res"},{"key":"1603_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471142735.im1525s104","volume":"104","author":"B Chassaing","year":"2014","unstructured":"Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014;104:1\u20135.","journal-title":"Curr Protoc Immunol."},{"issue":"9","key":"1603_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/gut.2009.197822","volume":"59","author":"C Bauer","year":"2010","unstructured":"Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59(9):1192\u20139.","journal-title":"Gut"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01603-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01603-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T14:07:00Z","timestamp":1662386820000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01603-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01603-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"404"}}